BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
BioNTech SE (Nasdaq: BNTX) has announced that it will release its second quarter 2024 financial results on Monday, August 5, 2024. The company will also host a conference call and webcast on the same day at 8:00 a.m. EDT (2:00 p.m. CEST) to discuss the financial results and provide a corporate update.
Investors, financial analysts, and the general public can access the live conference call via telephone by registering through a provided link. The slide presentation and audio of the webcast will be available through another link. Participants can also access the materials via the 'Events & Presentations' page in the Investor Relations section of BioNTech's website. A replay of the webcast will be archived on the company's website for 30 days following the call.
BioNTech SE (Nasdaq: BNTX) ha annunciato che pubblicherà i suoi risultati finanziari del secondo trimestre 2024 lunedì 5 agosto 2024. L'azienda ospiterà anche una chiamata in conferenza e una trasmissione in diretta lo stesso giorno alle 8:00 EDT (14:00 CEST) per discutere i risultati finanziari e fornire aggiornamenti aziendali.
Investitori, analisti finanziari e il pubblico possono accedere alla chiamata in conferenza dal vivo tramite telefono registrandosi attraverso un link fornito. La presentazione delle diapositive e l'audio della trasmissione saranno disponibili tramite un altro link. I partecipanti possono anche accedere ai materiali tramite la pagina 'Eventi & Presentazioni' nella sezione Relazioni con gli Investitori del sito web di BioNTech. Una registrazione della trasmissione sarà archiviata sul sito dell'azienda per 30 giorni dopo la chiamata.
BioNTech SE (Nasdaq: BNTX) ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 el lunes 5 de agosto de 2024. La compañía también llevará a cabo una llamada en conferencia y una transmisión en vivo el mismo día a las 8:00 a.m. EDT (2:00 p.m. CEST) para discutir los resultados financieros y proporcionar una actualización corporativa.
Los inversores, analistas financieros y el público en general pueden acceder a la llamada en conferencia en vivo por teléfono registrándose a través de un enlace proporcionado. La presentación de diapositivas y el audio de la transmisión estarán disponibles a través de otro enlace. Los participantes también pueden acceder a los materiales a través de la página 'Eventos y Presentaciones' en la sección de Relaciones con Inversores del sitio web de BioNTech. Una repetición de la transmisión será archivada en el sitio web de la empresa durante 30 días después de la llamada.
BioNTech SE (Nasdaq: BNTX)는 2024년 2분기 재무 결과를 2024년 8월 5일 월요일에 발표할 것이라고 발표했습니다. 이날 오전 8시 EDT (오후 2시 CEST)에 재무 결과를 논의하고 기업 업데이트를 제공하기 위해 전화 회의 및 웹캐스트를 진행할 예정입니다.
투자자, 재무 분석가 및 일반 대중은 제공된 링크를 통해 등록하여 전화로 실시간 회의에 접근할 수 있습니다. 슬라이드 프레젠테이션 및 웹캐스트 오디오는 다른 링크를 통해 이용할 수 있습니다. 참가자는 BioNTech 웹사이트의 투자자 관계 섹션에 있는 '이벤트 및 프레젠테이션' 페이지를 통해 자료에도 접근할 수 있습니다. 웹캐스트 녹화는 통화 후 30일 동안 회사 웹사이트에 보관됩니다.
BioNTech SE (Nasdaq: BNTX) a annoncé qu'il publiera ses résultats financiers du deuxième trimestre 2024 le lundi 5 août 2024. L'entreprise organisera également une conférence téléphonique et un webinaire le même jour à 8h00 EDT (14h00 CEST) pour discuter des résultats financiers et fournir une mise à jour sur l'entreprise.
Les investisseurs, les analystes financiers et le grand public peuvent accéder à la conférence téléphonique en direct par téléphone en s'inscrivant via un lien fourni. La présentation des diapositives et l'audio du webinaire seront disponibles via un autre lien. Les participants peuvent également accéder aux documents via la page 'Événements & Présentations' dans la section Relations Investisseurs du site web de BioNTech. Un enregistrement du webinaire sera archivé sur le site de l'entreprise pendant 30 jours après l'appel.
BioNTech SE (Nasdaq: BNTX) hat angekündigt, dass es am Montag, den 5. August 2024 seine finanziellen Ergebnisse für das zweite Quartal 2024 veröffentlichen wird. Das Unternehmen wird am selben Tag um 8:00 Uhr EDT (14:00 Uhr CEST) eine Telefonkonferenz und eine Webcast durchführen, um die finanziellen Ergebnisse zu besprechen und ein Unternehmens-Update zu geben.
Investoren, Finanzanalysten und die Öffentlichkeit können über eine bereitgestellte Registrierung einen Zugang zur Live-Telefonkonferenz erhalten. Die Präsentationsfolien und der Audio des Webcasts werden über einen anderen Link verfügbar sein. Teilnehmer können die Materialien auch über die Seite 'Veranstaltungen & Präsentationen' im Bereich Investor Relations der BioNTech-Website abrufen. Eine Aufzeichnung des Webcasts wird für 30 Tage nach der Konferenz auf der Unternehmenswebsite archiviert.
- None.
- None.
MAINZ, Germany, July 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2024 on Monday, August 5, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this link.
Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page in the Investor Relations section of the Company’s website at www.BioNTech.com. A replay of the webcast will be made available shortly after the call and archived on the Company’s website for 30 days following the call.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Biotheus, DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron.
For more information, please visit www.BioNTech.com.
CONTACTS
Investor Relations
Victoria Meissner, M.D.
+1 617 528 8293
Investors@biontech.de
Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de
FAQ
When will BioNTech (BNTX) report its Q2 2024 financial results?
What time is BioNTech's (BNTX) Q2 2024 earnings call scheduled for?
How can investors access BioNTech's (BNTX) Q2 2024 earnings call?
Where can I find the replay of BioNTech's (BNTX) Q2 2024 earnings call?
